The condition of the corneal epithelium is a critical determinant of corneal transparency and clear vision. The corneal epithelium serves as a barrier to protect the eye from external insults, with its smooth surface being essential for its optical properties. Disorders of the corneal epithelium include superficial punctate keratopathy, corneal erosion, and persistent epithelial defects (PEDs). The prompt resolution of these disorders is important for minimization of further damage to the cornea. Currently available treatment modalities for corneal epithelial disorders are based on protection of the ocular surface in order to allow natural healing to proceed. PEDs remain among the most difficult corneal conditions to treat, however. On the basis of characterization of the pathobiology of PEDs at the cell and molecular biological levels, we have strived to develop new modes of treatment for these defects. These treatments rely on two key concepts: provision of a substrate, such as the adhesive glycoprotein fibronectin, for the attachment and migration of corneal epithelial cells, and activation of these cells by biological agents such as the combination of substance P and insulin-like growth factor-1 (IGF-1). Central to both approaches is the role of the fibronectineintegrin system in corneal epithelial wound healing. Determination of the minimum amino acid sequences required for the promotion of corneal epithelial wound closure by fibronectin (PHSRN) and by substance P (FGLM-amide) plus IGF-1 (SSSR) has led to the development of peptide eyedrops for the treatment of PEDs that are free of adverse effects of the parent molecules.
Abbreviations: EGF, epidermal growth factor; FGF, fibroblast growth factor; IGF, insulin-like growth factor; SPK, superficial punctate keratopathy; PED, persistent epithelial defect; ECM, extracellular matrix; u-PA, urokinase-type plasminogen activator; HCE, simian virus 40-transformed human corneal epithelial cell; IL, interleukin; PKC, protein kinase C; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; JNK, c-Jun NH 2 -terminal kinase; ZO, zonula occludens; CGRP, calcitonin generelated peptide. * All clinical research of the authors presented in this review was performed with approval of the appropriate ethics committee and with informed consent of the subjects.
Introduction
Both the structure and function of the cornea are rather simple compared with those of other tissues and organs. The cornea nevertheless plays a key role in vision as a result of its transparency and refractive power. It is thus necessary for the cornea to be clear and transparent for it to allow external light to enter through the pupil and lens and to reach the retina. The smooth surface of the cornea and its stable shape with appropriate refractive power are also essential for the focusing of external light and formation of clear images on the retina.
The human cornea contains a stratified epithelium at its external surface with a thickness of~50 mm, which accounts for 10% of the total thickness of the cornea. This epithelium comprises five or six layers of epithelial cells, including basal cells, wing cells, and superficial cells. Only basal cells have mitogenic activity, and they differentiate consecutively into wing cells and superficial cells. The superficial cells undergo desquamation as a result either of the mechanical friction associated with blinking (Lemp and Mathers, 1989; Mathers and Lemp, 1992; Pfister, 1973) or of apoptosis (Glaso et al., 1993; Kinoshita et al., 2001; Wilson, 1996, 1997; Wilson et al., 1996) . The mechanisms of cell-to-cell and cell-to-matrix interaction differ among the cell layers of the epithelium. Integrins, which serve as receptors for extracellular matrix (ECM) proteins, are expressed predominantly in the basal epithelial cells and mediate the tight adherence of these cells to the basement membrane. Gap junctions composed of connexin 43 are present only in basal cells and subserve intercellular communication between these cells. On the other hand, tight junctions, consisting of proteins such as zonula occludens (ZO)-1 and occludin, are present mainly in the superficial cells and confer barrier properties on the entire epithelium. A well-layered structure and orderly differentiation process are essential for the maintenance of corneal transparency and clarity (Nishida and Saika, 2011; Suzuki et al., 2003) .
The body has acquired passive protective and active repair mechanisms through the process of evolution in order to survive environmental insults. These mechanisms maintain the normal structure and function of the body as well as repair injured components to restore their structure and function. Epithelia form the boundary of the body with the external environment, covering its entire surface and protecting the internal milieu from outside insults. Damage to or disorders of epithelia often result in inflammation or the activation of fibroblasts and other cell types that are normally isolated from the external environment. Epithelial wound healing is thus an important biological process for restoration of the normal structure and function of tissues and organs subjected to mechanical, chemical, or biological insults. Otherwise, a loss of or break in tissue continuity would persist and tissue dysfunction would proceed.
The ocular surface is covered by the corneal and conjunctival epithelia, with the transition between these two epithelia being located at the limbus. Stem cells for the corneal epithelium are located at the limbus (Dua and Azuara-Blanco, 2000; OseiBempong et al., 2013; O'Sullivan and Clynes, 2007; Yoon et al., 2014) .
The conjunctival epithelium is folded to form the bulbar conjunctiva and palpebral conjunctiva. The anatomic characteristics of the corneal and conjunctival epithelia are distinct (Fukuda and Nishida, 2010b; Kinoshita et al., 2001) . Whereas both face the external environment, the corneal epithelium forms a tight barrier but the conjunctival epithelium does not. The cornea is also an avascular tissue, whereas the conjunctiva has an extensive vascular system. Furthermore, immune cells, such as mast cells, lymphocytes, and eosinophils, are abundant in the conjunctiva, but they are present in only low numbers in the cornea (Allansmith et al., 1978; Morgan et al., 1991) . In addition, mucin-secreting (goblet) cells are present only in the conjunctival epithelium (Argueso and Gipson, 2001; Gipson, 2004) . Given that the conjunctival and corneal epithelia are separated by tear fluid (Gipson, 2007) , inflammatory reactions in the conjunctiva can spread to the cornea through tear fluid and vice verse (Nishida, 2010a) .
Tear fluid is an evolutionary adaptation to life on dry land that arose to prevent desiccation of the ocular surface. In addition, tear fluid provides a pathway for inflammatory cells and various cytokines and chemokines (Nishida, 2006) . Dry eye is a multifactorial disease of tear fluid and the ocular surface that is characterized by symptoms of ocular discomfort, visual disturbance, and tear film instability and can result in damage to the ocular surface (Lemp et al., 2007) . The condition of tear fluid affects that of the corneal epithelium. Conversely, the condition of the cornea and conjunctiva influences the quality of tear fluid. The corneaetear fluideconjunctiva axis thus plays a key role in inflammatory reactions at the ocular surface and in ocular surface disturbances.
Although the surface of the cornea is continually exposed to environmental threats as a result of its anatomic location, the corneal epithelium is equipped with active repair mechanisms. In the case of most corneal epithelial injuries, the defects are resurfaced rapidly by the remaining epithelial cells at a rate of about 1 mm 2 /h (Hanna et al., 1961) and without serious aftereffects.
Under certain conditions, however, the cornea develops various types of epithelial disorders, such as superficial punctate keratopathy, corneal erosion, and persistent corneal epithelial defects (also known as nonhealing epithelial defects). These disorders may arise as a result of changes either in the activities of epithelial cells or in conditions such as the shape of the lid margin, inflammation at the ocular surface, the amount or quality of tear fluid, or nerve activity. Furthermore, in the presence of systemic disease or a deteriorating local environment, complete repair of corneal epithelial damage is not achieved and more serious conditions can develop. Limbal stem cells serve as a reservoir for corneal epithelial cells, so that depletion or loss of function of these stem cells can result in a lack or deficiency of healthy (terminally differentiated) corneal epithelial cells and in the consequent development of persistent epithelial defects (Mort et al., 2012; Notara et al., 2010; OseiBempong et al., 2013; Secker and Daniels, 2008; Yoon et al., 2014) Thymosin b4 is a small protein of 43 amino acids (Low et al., 1981) that stimulates hair growth and corneal epithelial wound healing through promotion of stem cell migration, inhibition of corneal epithelial cell apoptosis, and an anti-inflammatory action (Philp et al., 2007; Sosne et al., 2001 Sosne et al., , 2002 Sosne et al., , 2004 Sosne et al., , 2006 Sosne et al., , 2007a . Clinically, thymosin b4 has been found to be effective for the treatment of neurotrophic keratopathy and dry eye syndrome (Dunn et al., 2010; Sosne et al., 2012) .
Unfortunately, few drugs are available to treat corneal epithelial disorders based on the pathobiology of the symptoms. Available treatments include artificial tears of various osmolarities, hyaluronan eyedrops, oily ointments, steroids, nonsteroidal antiinflammatory drugs (NSAIDs), and immunosuppressive agents. None of these treatments target the activity of corneal epithelial cells, however. Rather, they protect the corneal surface either directly or by attenuation of inflammation, thereby improving the local environment or circumstances in order to support the natural healing process. In addition, patients with ocular surface infections can be treated with antibiotics or other antibacterial, antiviral, or antifungal agents. Although the number of individuals with nonhealing epithelial defects of the cornea is relatively small, there is an unmet need for drugs that target corneal epithelial cells in order to facilitate epithelial wound healing and to restore the smooth surface of the cornea.
Over the last several decades, many studies have investigated factors that might accelerate the wound healing process in the corneal epithelium (Imanishi et al., 2000; Nishida and Tanaka, 1996; Schultz et al., 1992; Wilson et al., 2001 ). These factors have included epidermal growth factor (EGF) (Daniele et al., 1979; Ho and Elliott, 1975; Nishida et al., 1990; Schultz et al., 1988 ; Soong Watanabe et al., 1987 Watanabe et al., , 1988 Yu et al., 2010) as well as various other growth factors such as fibroblast growth factor (FGF), hepatocyte growth factor, keratinocyte growth factor, and nerve growth factor (Gospodarowicz et al., 1977; Grant et al., 1992; Lambiase et al., 2000 Lambiase et al., , 2012 Sotozono et al., 1994; Wilson et al., 1993) . In addition, extracellular matrix components such as fibronectin have been shown to facilitate corneal epithelial wound healing (Nishida, 2010b (Nishida, , 2012 . A major drawback of many of these biologically active agents has been the induction of unwanted effects on various components of the anterior segment of the eye, such as the induction of corneal neovascularization by EGF. It is thus important to identify factors that promote corneal epithelial wound healing without adverse effects, or to modify agents so that they retain beneficial effects but lack undesirable effects of the parent molecule.
In this review, we will address new drug development strategies for the treatment of ocular surface disturbances, with emphasis on persistent epithelial defects of the cornea. We will present possible targets for such drugs and as well as our scientific and clinical findings with fibronectin and the combination of substance P and insulin-like growth factor-1 (IGF-1).
Targets for new drug development for corneal epithelial pathologies
Whenever a patient is encountered whose corneal epithelial disorder cannot be cured by currently available prescription drugs or surgery, the need for the development of new treatments is apparent. To clarify the targets for new drug development, we first need to consider the various types of corneal epithelial disorder and their origins. Corneal epithelial disorders can generally be classified into three categories based on pathophysiology: superficial punctate keratopathy, corneal erosion, and persistent corneal epithelial defects (Fig. 1, Table 1 ).
Superficial punctate keratopathy
Superficial punctate keratopathy (SPK) affects only the superficial layer of the corneal epithelium, and it is identified by punctate fluorescein staining at the corneal surface. Laser confocal biomicroscopy reveals the presence of dispersed defects encompassing individual or a few superficial epithelial cells (Zhivov et al., 2006) , with the punctate staining apparent with fluorescein corresponding to each cellular defect (Mokhtarzadeh et al., 2011) . SPK is thought to result from a loss of balance between the differentiation and apoptosis of basal, wing, and superficial epithelial cells, and it may be triggered by factors in the environment surrounding the cornea. The corneal epithelium forms a secure barrier to water, ions, and various deleterious agents Mishima and Hedbys, 1967) . This barrier function of the corneal epithelium is conferred as a result of the formation of intercellular tight junctions containing ZO-1 between superficial epithelial cells. The permeability of the corneal epithelium is measured clinically by fluorophotometry (Kinoshita et al., 2001 ) and is increased with age, in individuals with diabetes mellitus or dry eye syndrome, as well as prior to the onset of SPK (Chang and Hu, 1993; Gobbels and Spitznas, 1992; Gobbels et al., 1989; Yokoi and Kinoshita, 1995) . SPK is one of the signs of dry eye (Amano et al., 2006; Kaido et al., 2011; Miyata et al., 2003) , and a low level of tear secretion, an excess of cytokines in tear fluid, or exposure to toxic materials such as the preservatives in prescription eyedrops may induce the punctate loss of superficial epithelial cells (DeRosa, 1998) . Furthermore, a pathological condition affecting the basement membrane, such as anterior basement membrane dystrophy or diabetic keratopathy, may influence the differentiation of corneal epithelial cells and result in the development of SPK (Schultz et al., 1981; Wakuta et al., 2007) .
The choice of drugs for the treatment of SPK depends on its etiology. In the case of low tear secretion, the administration of artificial tear fluid or viscous hyaluronan eyedrops is preferred. Steroid or NSAID eyedrops should be administered in the presence of conjunctival inflammation or meibomian gland dysfunction. Overnight coverage of the corneal surface with oily ointment is also effective in some cases. Two new drugs, diquafosol and rebamipide, have recently been approved in Japan for the treatment of dry eye syndrome. Diquafosol is a P2Y2 purinergic receptor agonist that stimulates the release of water by conjunctival epithelial cells (Lau et al., 2014; Murakami et al., 2004; Shaver, 2001; Shimazaki-Den et al., 2013) . It also possesses scavenging activity for free radicals and stimulates cyclooxygenase-2 activity and consequent prostaglandin production. Clinical studies performed in Japan have shown that diquafosol is effective in reducing the extent of punctate fluorescein staining of the corneal epithelium, a major objective sign of dry eye syndrome (Koh et al., 2013; Matsumoto et al., 2012; Nakamura et al., 2012; Nichols et al., 2004; Takamura et al., 2012) . Rebamipide has anti-inflammatory actions in the gastrointestinal tract (Genta, 2003; Haruma and Ito, 2003) and has long been prescribed as an oral drug for the treatment of gastritis (Arakawa et al., 2005 (Arakawa et al., , 1995 . It also exerts anti-inflammatory actions at the ocular surface. It thus increases the secretion of mucin-like substances by corneal epithelial cells Urashima et al., 2012) , suppresses cytokine production by corneal epithelial cells (Fukuda et al., 2014) and conjunctival epithelial cells (Tanaka et al., 2013; Ueta et al., 2013) , up-regulates barrier function of the corneal epithelium (Kimura et al., 2013; Tanaka et al., 2013) , and thereby reduces epithelial punctate keratopathy in the rabbit cornea and conjunctiva (Urashima et al., 2004) . In the clinical setting, the administration of rebamipide ophthalmic suspension ameliorates SPK associated with dry eye syndrome (Itakura et al., 2013; Kashima et al., 2012 Kashima et al., , 2014 Kinoshita et al., 2014 Kinoshita et al., , 2013 .
SPK is thus a major sign of dry eye syndrome and is caused by various different factors (Lemp et al., 2007) . Although several local treatmentsdsuch as artificial tears, hyaluronan eyedrops, diquafosol eyedrops, and rebamipide suspensiondimprove the microenvironment of the corneal surface and thereby ameliorate SPK and dry eye, new drugs that target the function of corneal epithelial cells would be expected to provide a better option for such treatment.
Corneal erosion
Corneal erosion is characterized by loss of the entire thickness of the corneal epithelium. There are two types of corneal erosion: simple and recurrent. Simple erosion is usually the result of injury to the corneal surface and is apparent as a sharply defined region of fluorescein staining. This staining reveals that the remaining epithelial cells are firmly attached to the underlying basement membrane. The remaining epithelial cells begin to migrate over the area of the defect immediately after the injury, resulting in relatively rapid coverage of the injury site in most cases. Active treatment is not required for this type of injury in the absence of underlying conditions, such as infection or diabetes, that might delay or block epithelial wound healing. Prophylactic administration of antibacterial agents may be recommended.
Recurrent erosion is caused by shearing forces acting at the corneal surface, such as those that might result from a nail injury, and it is associated with anterior basement membrane dystrophy, such as lattice corneal dystrophy. Some individuals with diabetes show a tendency to develop recurrent erosion. Retro-illumination reveals the presence of small transparent deposits under the damaged epithelium of individuals with recurrent corneal erosion. The healing pattern for each episode of recurrent erosion is similar to that for simple erosion. Current treatments are identical to those for simple erosion, although fine needle puncture has been found to be effective for prevention of recurrence (Watson and Barker, 2007; Watson et al., 2012) . Adhesion of the epithelium is weak in cases of recurrent erosion, however, and mild debridement is readily achieved with a fine cotton swab. We have treated such patients by epithelial debridement followed by removal of the underlying deposits by washing. There is a need for new treatments that would accelerate epithelial wound healing by stimulating epithelial cell migration and adhesion to the underlying matrix .
Persistent corneal epithelial defects (nonhealing epithelial defects)
Persistent epithelial defects (PEDs) of the cornea occur when the total thickness of the epithelium is lost and there is no sign of the initiation of epithelial resurfacing by remaining epithelial cells or intact stem cells of the epithelium at the limbus. Clinically, this condition is characterized by fluorescein staining of the defect area and ground glass-like opacity surrounding the defect area. The margin of the defect area shows weak adhesion of the remaining epithelium to the underlying basement membrane or stroma. The principal difference between simple corneal erosion and PEDs, both of which show a loss of all epithelial layers, is the condition of the epithelium in the marginal area. The epithelium in the marginal area adheres firmly to the underlying matrix in simple corneal erosion, with the result that fluorescein dye does not seep under the remaining epithelium. In contrast, in the case of PEDs, seeping of fluorescein under the marginal epithelium renders the margin indistinct and fuzzy. Indeed, it is possible to predict whether epithelial resurfacing will take a long time or perhaps never begin on the basis of the condition of the epithelium at the margin of the defect area.
PEDs develop most commonly in patients with dry eye, in whom the quantity or quality of tear fluid is diminished, and in those with reduced corneal sensation as a result of nerve damage or degeneration. The lack of stimulation of corneal epithelial cells by growth factors and cytokines in tear fluid or by neuropeptides released from the trigeminal nerve results in failure of the corneal epithelium to maintain a normal structure and to initiate a healing response. These pathological backgrounds can lead to the development of various types of corneal epithelial disturbance (Lemp et al., 2007; Smith et al., 2007) , the most severe of which are PEDs associated with dry eye syndrome. Dysfunction of the trigeminal nerve may lead to serious corneal epithelial disturbances referred to as neurotrophic keratopathy. Possible causes of neurotrophic keratopathy include systemic diseases such as diabetes mellitus and certain genetic disorders, central nervous system abnormalities such as brain tumors and complications of neurosurgery, and various insults to the ocular surface such as herpes simplex virus infection, penetrating keratoplasty or LASIK surgery, abuse of topical anesthetics, and toxicity of ophthalmic drugs (Lambiase et al., 1999; Nishida, 2005; Nishida and Yanai, 2009) . Clinical regeneration of trigeminal nerve fibers is not currently possible, and management of neurotrophic keratopathy remains difficult (Bonini et al., 2003; Goins, 2005; Nishida, 2010b; Okada et al., 2010; Pushker et al., 2001; Reynolds and Kabat, 2006) .
PEDs are also associated with shield ulcer in individuals with vernal or atopic keratoconjunctivitis (Cameron, 1995; Kumagai et al., 2006; Kumar, 2009) . In this instance, the underlying pathology may differ from that of PEDs associated with dry eye or neurotrophic keratopathy. Severe allergic reactions in the palpebral conjunctiva result in the release of histamine, leukotrienes (Garceau and Ford-Hutchinson, 1987) , proteinases (Kumagai et al., 2002) , as well as eosinophil-derived cytotoxic proteins such as major basic protein, eosinophil cationic protein, eosinophil peroxidase, and eosinophil-derived neurotoxin (Trocme et al., 1989) . Eosinophil-derived cytotoxic proteins in particular can damage corneal epithelial cells and retard corneal epithelial wound healing (Fukuda and Nishida, 2010a,b; Trocme et al., 1989) . The development of giant papillae in vernal keratoconjunctivitis induces mechanical stress that also results in delayed corneal epithelial resurfacing. Furthermore, the deposition of fibrin and mucous cellular debris at the site of epithelial defects results in the formation of plaque that prevents the attachment and migration of corneal epithelial cells and thereby leads to persistence of epithelial defects. Treatment of PEDs in such patients includes suppression of allergic reactions, removal of mechanical stimuli in the form of giant papillae, removal of plaque, and facilitation of corneal epithelial resurfacing (Fukuda et al., 2010; Guo et al., 2013; Kumagai et al., 2005; Reddy et al., 2013) .
Chemical or thermal burns of the cornea and Stevens-Johnson syndrome are associated with stem cell deficiency at the limbus and a consequent insufficient supply of corneal epithelial cells for epithelial resurfacing and the persistence of epithelial defects. Although the signs of PEDs appear to be identical regardless of whether limbal stem cells are intact or not, it is important to differentiate PEDs with intact stem cells from those caused by stem cell deficiency.
There are no specific and curative treatment modalities for PEDs of the cornea. Whereas the development of drugs that target directly the function of corneal epithelial cells and thereby ameliorate corneal epithelial disturbances is desirable, most currently available ophthalmic drugs serve to improve the environment at the ocular surface. Only symptomatic treatments have been applied, with the expectation that natural epithelial resurfacing may occur. Forced eye patches, therapeutic soft contact lenses (Blackmore, 2010; Choi and Chung, 2011; Schrader et al., 2006) , oily ointments, tarsorrhaphy (Baum, 1987; Cosar et al., 2001; Panda et al., 1999) , and amniotic membrane transplantation (Brijacak et al., 2008; Gris et al., 2002; Lee and Tseng, 1997; Panda et al., 1999; Turkoglu et al., 2014) have thus been applied to protect the corneal surface from external insults. In addition, administration of artificial tears, viscoelastic (such as hyaluronan or chondroitin sulfate) eyedrops, punctal plugs (Tai et al., 2002) , and fibrin glue (Sumich et al., 2003) as well as improved lid hygiene have been tried. Autologous serum eyedrops (Geerling et al., 2004; Matsumoto et al., 2004; Mukerji et al., 2002; Noble et al., 2004) , umbilical cord serum (Vajpayee et al., 2003; Yoon et al., 2005 Yoon et al., , 2007 , EGF (Daniele et al., 1992) , and plasma rich in growth factors (Cho et al., 2013; Geerling et al., 2004; Kim et al., 2012; Lopez-Plandolit et al., 2010; Mukerji et al., 2002; Poon et al., 2001; Tsubota et al., 1999b; Vajpayee et al., 2003) have also been examined in the clinical setting, but none of these treatment modalities has been confirmed to be effective scientifically (Pan et al., 2013) .
Concepts for new drug development for PEDs
Cavanagh and colleagues stated in 1976 that "The endogenous biochemical control mechanisms which regulate epithelial cell movement, mitosis, and the synthesis of basal lamina must be understood first in order to interpret correctly any pathologic alteration" (Cavanagh et al., 1976) . Even today, almost 4 decades later, this contention is still relevant. Progress in cell and molecular biology has provided insight into epithelial wound healing and the roles of growth factors, cytokines, proteases, and extracellular matrix (ECM) proteins in this process.
Epithelial resurfacing is regulated by many biologically active agents including growth factors, cytokines, and chemokines (Lim et al., 2003; Suzuki et al., 2003; Werner and Grose, 2003) . Furthermore, the condition of the basement membrane on which epithelial cells migrate is another important determinant of this process. The degradation of basement membrane components is mediated in part by plasmin and urokinase-type plasminogen activator (u-PA), the latter of which is secreted from injured corneal epithelial cells as well as from activated keratocytes in the corneal stroma (Morimoto et al., 1993) . Excessive degradation of the basement membrane prevents the adherence of epithelial cells and their subsequent migration (Berman et al., 1983) . Plasminogen activator activity is increased in the tear fluid of individuals with PEDs (Berta et al., 1990) .
Adhesion of epithelial cells to underlying ECM through the interaction of cellular integrins with fibronectin is required in the early stages of active cell locomotion. Detachment of cells from the matrix is also required, however, for the active movement or migration of these cells, and this detachment is mediated in part by degradation of matrix proteins. The addition of either immunoglobulin G specific for human u-PA or protease inhibitors was thus shown to retard migration of the rabbit corneal epithelium ex vivo, indicating that u-PA activity is essential for this process (Morimoto et al., 1993) . Immunostaining and in situ zymography of the wounded rabbit cornea have also revealed that u-PA expression and activity are restricted to the leading edge of the migrating epithelium at the wound margin (Watanabe et al., 2003) . Annexin A5, a Ca 2þ -dependent phospholipid-binding protein, up-regulates u-PA release from corneal epithelial cells and was found to promote corneal epithelial wound healing both in vitro and in vivo (Watanabe et al., 2006) . The migration of corneal epithelial cells thus requires not only cell attachment to fibronectin in the ECM but also cellular detachment that is mediated by the degradation of fibronectin and triggered by the release of cellular u-PA.
Given that corneal epithelial adhesion and migration are regulated by biological factors present in tear fluid, the pathology of PEDs depends largely on the amount of tear fluid and the amounts and types of biologically active agents therein (Barabino et al., 2012; Kinoshita et al., 2001; Lim et al., 2003; Nishida, 2006; Pflugfelder, 2011) . It is also influenced by the presence of melting of stromal collagen (corneal ulceration) and of systemic diseases such as diabetes. In addition, PEDs are associated with low corneal sensation resulting from damage to the trigeminal nerve, as occurs in individuals with neurotrophic keratopathy. Corneal sensation and tear fluid secretion are connected by the trigeminal nerve reflex, with the loss of corneal sensation often being accompanied by reduced tear secretion. The loss of corneal sensation may also give rise to various types of corneal epithelial disorders directly as a result of the loss of stimuli from nerve endings in the corneal epithelium. Substance P, a sensory neurotransmitter, is present in normal human tear fluid at a concentration of~300 pg/mL, with this value not being dependent on age or sex. Fragments of substance P are also detected in tear fluid, suggesting that this neurotransmitter is degraded by tear enzymes . In patients with corneal hypesthesia, however, the concentration of substance P in tear fluid is reduced to about two-thirds of the normal value (Yamada et al., 2000) .
Homeostasis of corneal epithelial structure and function is thus maintained in large part by the actions of growth factors and neural factors in tear fluid, by signals dependent on the condition of the basement membrane, and by the direct effects of neurotransmitters released from nerve endings. Furthermore, the condition of tear fluid, corneal sensation, and the ECM are important determinants of the pathobiology of PEDs. PEDs develop in individuals with dry eye as a result of the low quantity or quality of tear fluid. They also often emerge after recovery from corneal infections such as herpetic keratitis and microbial keratitis. In addition, individuals with diabetes develop diabetic keratopathy after damage to the corneal epithelium as a result of delayed epithelial resurfacing.
Given that weak adhesion of remaining corneal epithelial cells to the underlying provisional matrix is implicated in the pathobiology of PEDs, we have focused our research on finding substrates that might contribute to a curative treatment, bearing in mind the key role of the adhesive glycoprotein fibronectin in epithelial resurfacing. Concepts for new drug development for PEDs thus include both the provision of a scaffold to stimulate the adhesion and migration of epithelial cells as well as the active promotion of these processes through up-regulation of integrin chains that serve as a receptor for fibronectin.
Epithelial healing process in the cornea

Epithelial wound healing
Thoft and Friend proposed that the normal corneal epithelium is maintained by the balance between proliferation of basal epithelial cells (X), centripetal movement of epithelial cells (Y), and cell loss from the corneal surface (Z) (Thoft and Friend, 1983) . For the centripetal movement of epithelial cells, the presence of intact and healthy limbal stem cells is essential. These stem cells are thus required for repair of the damaged corneal epithelium, with epithelial resurfacing being delayed or not occurring at all in cases of stem cell deficiency.
The turnover rate of epithelial cells in the human cornea is~1 week (Hanna et al., 1961; Hanna and O'Brien, 1960) , whereas that of keratocytes and ECM in the corneal stroma is on the order of 2e3 years and corneal endothelial cells do not turn over. Epithelial disorders should thus be resolved within~1 week with appropriate treatment, whereas pathologies of the stroma require a much longer time to clear up after the resolution of acute inflammation. Given the limited recovery capacity of endothelial cells, it is important that these cells are protected from inflammatory attack or other insults.
The function of corneal cells is regulated by various biologically active humoral agents and neural factors as well as by cell-to-cell and cell-to-matrix interactions (Imanishi et al., 2000; Suzuki et al., 2003; Wilson et al., 2001) . Soluble factors are supplied by tear fluid, aqueous humor, the limbal vascular system, and nerve fibers. In addition, cells of the corneal epithelium, stroma, and endothelium interact with each other by cell-to-cell contact and by secreting various biologically active substances such as growth factors and cytokines (Ko et al., 2012 , 2008a ,b, 2014 , 2010a ,b, Ko et al., 2009a . The function and fate of the corneal epithelium are regulated predominantly by factors derived from tear fluid and nerve fibers as well as by keratocytes.
The largest boundary between the body and the environment is the skin, and the mechanism of cutaneous wound healing has been extensively investigated. Injury to a vascularized tissue such as the skin is followed by four phases of the healing process: (1) inflammation (including blood coagulation and the accumulation of bloodderived cells such as platelets and neutrophils), (2) epithelialization, (3) granulation, and (4) tissue remodeling (Clark, 1996; Singer and Clark, 1999) . In most parts of the body, with exceptions such as the cornea and joints, there are blood capillaries within a distance of 50 mm from any cell. Any injury to such tissues is thus accompanied by the breakdown of capillaries and consequent hemorrhage. The first step of the healing process includes the escape of blood components into the neighboring tissue and formation of a blood clot at the injury site. The repair process for epithelia then proceeds with the resurfacing of the defect area and granulation of the wound mediated by active proliferation of fibroblasts.
The cornea is unique in that it contains no blood capillaries. The initial stage of the wound healing process in the cornea thus differs from that in skin, with the leakage of blood components and blood clotting not occurring in the cornea. Instead, biological signals from the injured or dead corneal cells stimulate the secretion of various inflammatory cytokines from neighboring uninjured cells. In addition to the death of corneal cells resulting directly from injury, these newly secreted cytokines, so-called inflammatory cytokines, modify the physiology of the surviving cells and thereby trigger inflammation. Injuries to the cornea almost always involve the generation of epithelial defects, and healing then proceeds with reepithelialization of these defects followed by a tissue remodeling phase characterized by reassembly of the extracellular collagen matrix in the corneal stroma. These later phases of the wound healing process are thus common to vascularized skin and the avascular cornea.
The healing of corneal injuries must ensure that the cornea is transparent and has a smooth surface and the required curvature to restore vision. In contrast, wound repair in the skin must ensure only that the continuity and barrier function of this organ are restored. The formation of a scar at the site of a skin injury is not a serious problem as far as the function of the body is concerned. The healing of the cornea is thus a far more delicate and precise process.
Fibronectineintegrin interactions in corneal epithelial wound healing
As mentioned above, PEDs of the cornea are characterized by the loss of attachment of remaining corneal epithelial cells and by impaired epithelial migration. The absence of an appropriate substrate on which epithelial cells can attach and migrate thus appears central to the pathology of PEDs. With the goal of developing new drugs to treat this problem, we have focused on the substrate, cell attachment, and cell migration associated with the healing of corneal epithelial damage.
The fibronectineintegrin system
Fibronectin is a 440-kDa glycoprotein that comprises two identical chains connected by disulfide bonds. It functions as an adhesive protein and plays central roles in many biological processes involving cell adhesion, detachment, and migration. It thus contributes to wound healing, embryogenesis, development, and cancer metastasis (Hynes, 1990; Pankov and Yamada, 2002) .
Fibronectin is localized to the ECM and is also present in blood plasma. Fibronectin in human plasma is synthesized by hepatocytes and is present as a soluble dimer at a concentration of 300 mg/mL (Mosesson and Amrani, 1980; Mosesson and Umfleet, 1970; Mosher and Williams, 1978; Nishida et al., 1982a) . Plasma fibronectin was originally identified as a cold-insoluble globulin during fractionation of blood components (Morrison et al., 1948) . Insoluble cellular fibronectin is a component of the ECM. Cellular fibronectin is synthesized as a soluble dimer, mainly by fibroblasts but also by other cell types. After its secretion into the extracellular environment, fibronectin is assembled into an insoluble fibrillar matrix (Leiss et al., 2008; Mao and Schwarzbauer, 2005; Wierzbicka-Patynowski and Schwarzbauer, 2003) .
In addition to its integrin receptor, fibronectin has been found to bind to other ECM components (including collagen, gelatin, fibrin, heparin, heparan sulfate, and proteoglycans), to bacteria and viruses (including Staphylococcus aureus, Staphylococcus epidermidis, and retroviruses), to blood components (including fibrinogen and factor XIII), and to other proteins such as insulin-like growth factor binding protein 3 (IGFBP3) and transglutaminase. The binding of fibronectin to various molecules and to itself has been characterized at the molecular level.
The molecular structure of fibronectin is characterized by the presence of three types of module, including 12 type I modules, 2 type II modules, and 15 type III modules (Hynes, 1990; Pankov and Yamada, 2002) (Fig. 2) . In addition, there are alternatively spliced extra domains: EDB, EDA, and a variable region (IIICS). The binding of fibronectin to itself converts the soluble form of the protein into the insoluble fibrillar form. This self-assembly process thus contributes to formation of the insoluble fibronectin meshwork present in the extracellular environment. Fibronectin has at least two cell adhesion sites. The major cell-binding site of fibronectin is the amino acid sequence ArgeGlyeAsp (RGD) in the 10th type III domain. This sequence thus interacts with the integrin receptor at the cell surface. The amino acid sequence ProeHiseSereArgeAsn (PHSRN) in the ninth type III domain of fibronectin has also been found to support cell adhesion mediated by the RGD motif.
Integrins are transmembrane heterodimeric proteins that function as the receptors for various ECM proteins. They are composed of a and b subunits, with at least 18 a subunits and 8 b subunits having been identified in humans. The binding of integrins to ECM proteins such as fibronectin, collagen, laminin, tenascin, and fibrinogen serves to link these external proteins to the internal cytoskeleton of cells. Integrin a5b1 is the predominant cell surface receptor for fibronectin.
Integrins have two major physiological functions. First, they mediate the attachment of cells to the ECM. Second, they transmit signals from the outside to the inside of cells. Depending on the type of ECM protein and corresponding integrin involved, the receptoreligand interaction results in the activation of various intracellular signaling pathways that contribute to the regulation of cell behavior including cell survival, differentiation, proliferation, and migration (Das et al., 2014; Epifano and Perez-Moreno, 2012; Hynes, 1987 Hynes, , 2002 Labat-Robert, 2012; Longmate and Dipersio, 2014; Margadant et al., 2010; Parapuram et al., 2011; Stepp, 2006; Stepp et al., 1993) .
The fibronectineintegrin system in corneal epithelial wound healing
The fibronectineintegrin system is critical for the attachment, migration, and differentiation of corneal epithelial cells. In the normal nonwounded cornea, fibronectin is localized predominantly to Descemet's membrane, the basement membrane of the epithelium, and the stroma (Fujikawa et al., 1981; Kohno et al., 1987; Sramek et al., 1987; Suda et al., 1981; Tervo et al., 1986) . On the other hand, expression of the major fibronectin receptor, integrin a5b1, is restricted to the basal cells of the epithelium in the intact cornea (Grushkin-Lerner and Trinkaus-Randall, 1991; Lauweryns et al., 1991; Murakami et al., 1992; Paallysaho and Williams, 1991; Stepp et al., 1993; Tervo et al., 1991) .
Abrasion of the corneal epithelium is followed by the appearance of fibronectin in the exposed stroma and its subsequent gradual disappearance as healing proceeds (Fujikawa et al., 1981) . Fibronectin also appears at the cut surface of the stroma and epithelial cells migrate over the deposited fibronectin in response to a nonpenetrating injury to the cornea (Suda et al., 1981) . The fibronectin gradually disappears soon after the epithelial cells have covered the exposed stroma. All actively migrating epithelial cells, from basal to superficial cells, express integrin a5b1 after injury. As the epithelial defect is resurfaced, however, only basal epithelial cells facing the newly synthesized basement membrane express integrin a5b1 (Murakami et al., 1992) . This wellcoordinated appearance and disappearance of fibronectin and integrin in the corneal stroma and epithelial cells, respectively, suggest that the fibronectineintegrin system plays a central role in corneal epithelial wound healing. Indeed, various types of corneal insult or injury induce fibronectin up-regulation in the corneal stroma and thereby contribute to epithelial wound healing (Fujikawa et al., 1984; Nishida et al., 1982c; Ohashi et al., 1983; Spigelman et al., 1985) . This provisional fibronectin matrix provides a substrate for the migration of epithelial cells, with integrin expression in the epithelial cells allowing the cells to bind to the fibronectin and the fibronectineintegrin interaction signaling the cells to migrate. In addition to fibronectin, fibrinefibrinogen appears to be an essential component of the provisional matrix, whereas laminin and type IV collagen are not present (Fujikawa et al., 1984) .
3.3. Responses of corneal epithelial cells to fibronectin 3.3.1. Cell attachment, spreading, and migration on a fibronectin matrix As already mentioned, fibronectin is an adhesive glycoprotein that is essential for the attachment and spreading of corneal epithelial cells during corneal epithelial wound healing (Nakamura and Nishida, 1994a; Suzuki et al., 2003) . The number of corneal epithelial cells that attach to a culture plate coated with fibronectin increases in proportion to the concentration of coated fibronectin . Fibronectin stimulates epithelial cell migration as a result of its chemotactic, haptotactic, and chemokinetic activities .
A fibronectin substrate also stimulates the spreading of rabbit corneal epithelial cells, with the area of spreading depending on the concentration of fibronectin used to coat a culture plate in vitro. In spread cells, stress fibers of actin filaments are evenly distributed throughout the cytoplasm, whereas microtubules are apparent only in the perinuclear region. The presence of cytochalasin B (an inhibitor of actin polymerization) during corneal epithelial cell attachment and spreading on fibronectin was found to reduce the area of spreading to a greater extent than did the presence of colchicine (an inhibitor of microtubule polymerization). However, the addition of either agent after cell spreading had only a small effect on the spread area. These observations thus indicate that the formation of actin filaments is more important than that of microtubules for corneal epithelial cell spreading (Fukuda et al., 1990) . The attachment of simian virus 40-transformed human corneal epithelial (HCE) cells to fibronectin induces the accumulation of filamentous (F) actin and the formation of focal adhesions at the cell periphery as well as activation of the small GTPase Rac1, phosphorylation of p21-activated kinase (PAK), and localization of the K þ channel Kv2.1 to the leading edge of the cell in the direction of cell migration (Kimura et al., , 2010 . Fibronectin also induces tyrosine phosphorylation of the Cdc42-and Rac-specific guanine nucleotide exchange factor b-Pix in, as well as active ruffling at the leading edge of, these cells (Kimura et al., 2011) (Fig. 3) . Rabbit corneal epithelial cells respond differently to different matrix components such as fibronectin, collagen types I and IV, and laminin. Freshly isolated (uncultured) cells did not spread on fibronectin or laminin but did so on collagen types I and IV. After culture of the cells for 12 h or more, however, they also spread on fibronectin, whereas spreading of the cells on collagen types I and IV was the same regardless of the culture period (up to 20 h). Only a small number of cells spread on laminin at the highest concentration examined even after culture for 12 h or more. These observations with fibronectin suggested that fibronectin receptors are upregulated during culture (Nakagawa et al., 1990) . Attachment of corneal epithelial cells to fibronectin was inhibited in a concentration-dependent manner by addition to the culture medium of the synthetic peptide GRGDS, corresponding to the major cell-binding site of fibronectin, whereas the structurally similar control peptide GRGES had no such effect . Corneal epithelial cells thus bind to a fibronectin substrate via the RGD site of fibronectin.
Among the major components of basement membrane, laminin, fibronectin, and collagen types I and IV each promote the adhesion of HCE cells compared with bovine serum albumin as an inactive control. Fibronectin and collagen types I and IV, but not laminin, also increase the motility of these cells. Whereas collagen types I and IV each increase membrane movement in a manner independent of the direction of cell migration, fibronectin induces membrane movement only in the direction of cell migration. Fibronectin also induces the formation of thick bundles of F-actin and focal adhesions at the cell periphery as well as the localization of Kv2.1 at the leading edge of the cell, whereas laminin and collagen types I and IV elicit the formation of thinner bundles of F-actin and smaller focal adhesions and do not affect the localization of Kv2.1. Fibronectin thus modulates the directional migration of corneal epithelial cells as well as cell attachment and spreading (Kimura et al., 2010) . In addition to exogenous fibronectin, newly synthesized endogenous fibronectin was found to contribute to the attachment of human corneal epithelial cells in culture (Ohji et al., 1993) . Hyaluronan binds to a fibrin and heparin binding domain at the amino terminus of plasma fibronectin and may thereby increase the affinity of fibronectin for cells, resulting in the facilitation of corneal epithelial cell attachment to fibronectin (Nakamura et al., 1994) .
The effects of various growth factors and cytokines on the attachment and spreading of corneal epithelial cells have been investigated. EGF thus facilitates corneal epithelial resurfacing in vivo as well as promotes corneal epithelial cell attachment to fibronectin in vitro. This EGF-stimulated cell attachment to fibronectin was inhibited in a concentration-dependent manner by antibodies to fibronectin as well as by the GRGDSP peptide, implicating the fibronectineintegrin system in this effect of EGF.
Indeed, EGF increases the expression of integrin a5b1 in these cells (Nishida et al., 1992b) . Interleukin (IL)-6 and the combination of substance P and IGF-1 was also found to up-regulate integrin a5b1 expression in corneal epithelial cells Nakamura et al., 1998a; Ohashi et al., 1995) .
Promotion of corneal epithelial migration by fibronectin
We investigated whether fibronectin stimulates migration of the corneal epithelium with the use of an organ culture system for the rabbit cornea, in which pieces of full-thickness cornea are cultured for 24 h with test agents (Nishida et al., 1983a) . Immunofluorescence analysis revealed the appearance of fibronectin at the surface of the cut stroma as well as beneath migrating epithelial cells (Nishida et al., 1982b) , indicating that such fibronectin originates in the cornea itself. The addition of purified plasma fibronectin to the culture medium increased the path length of epithelial migration in a concentration-and time-dependent manner, showing that exogenous fibronectin stimulates epithelial migration (Nishida et al., 1983a) .
EGF facilitates corneal epithelial wound healing (Daniele et al., 1979; Ho and Elliott, 1975) , and we found that EGF also enhanced migration of the corneal epithelium in our organ culture system. The mechanism of action of EGF appeared to differ from that of fibronectin, however. Whereas fibronectin promoted sliding of the epithelium, EGF stimulated epithelial cell proliferation (Watanabe et al., 1987) . EGF also up-regulated the synthesis of fibronectin by the cultured cornea (Nishida et al., 1984b) . The stimulatory effect of EGF on corneal epithelial migration thus showed a time lag of at least 12 h, whereas that of fibronectin was essentially immediate. The maximal effect of fibronectin required its continuous presence. In contrast, whereas exposure to EGF for 6 h did not stimulate epithelial migration, exposure for 9 h resulted in the same stimulatory effect as did that for 24 h. Antibodies to fibronectin inhibited both the fibronectin-and EGF-stimulated migration of the corneal epithelium, whereas antibodies to EGF inhibited EGF-stimulated migration but not that induced by fibronectin. These results indicate that, unlike fibronectin, EGF need not be present after the epithelial cells have recognized its signal, and that the stimulatory effect of EGF is dependent on fibronectin whereas that of fibronectin is independent of EGF . As mentioned earlier, EGF also up-regulates the expression of integrin a5b1 in cultured rabbit corneal epithelial cells (Nakamura and Nishida, 1994b; Nishida et al., 1992b) . In addition to EGF, IL-6 stimulated corneal epithelial migration in our organ culture system in a manner dependent on fibronectin, presumably at least in part as a result of its up-regulation of integrin a5b1 expression (Nishida et al., 1992a; Ohashi et al., 1995) .
Before the application of fibronectin eyedrops to patients could be considered, we examined the effects of such eyedrops in animals. The administration of rabbit plasma fibronectin (0.75 mg/mL) to the cornea of rabbits subjected to epithelial debridement with the use of iodine vapor was found to accelerate epithelial resurfacing significantly compared with that observed after application of control phosphate-buffered saline eyedrops (Nishida et al., 1984a) . Administration of fibronectin eyedrops was also effective in promoting corneal epithelial wound healing in vitamin A-deficient rats (Watanabe et al., 1991) and in rats with streptozotocininduced diabetes (Nakamura et al., 1997d) , in both of which epithelial resurfacing is delayed.
Provision of a fibronectin substrate for promotion of epithelial migration in PEDs
Fibronectin plays an essential role in corneal epithelial wound healing by serving as a provisional matrix for the adhesion and migration of epithelial cells. Given that fibronectin might be degraded in the inflammatory lesion of corneal PEDs, it seemed possible that the administration of exogenous fibronectin to the damaged corneal epithelium might help to accomplish epithelial resurfacing in the clinical setting.
Autologous fibronectin eyedrops
A pure preparation of biologically active fibronectin was not available commercially in the early 1980s. Fibronectin is present in human blood plasma at a concentration of~300 mg/mL (LabatRobert et al., 1981; Mosher and Williams, 1978; Nishida et al., 1982a; Soria et al., 1980) , and it binds strongly to gelatin, or denatured collagen (Engvall and Ruoslahti, 1977) . With the use of gelatin affinity chromatography, we were therefore able to purify fibronectin from blood plasma and to prepare fibronectin eyedrops within 1 h (Nishida et al., 1982a) . To avoid any unfavorable and unexpected effects, we obtained the blood plasma from the patient who was going to be treated with the fibronectin eyedrops. Given the prevalence of blood-borne viral infections, such as those caused by hepatitis viruses and HIV, this approach remains the safest even today.
We initially treated three eyes of two patients with purified autologous fibronectin eyedrops. Both patients had PEDs of the cornea that had proved unresponsive to conventional therapy. In each case, re-epithelialization of the cornea began within 3 days, and the defects had disappeared completely within 3 weeks (Nishida et al., 1983c) . We subsequently treated 20 cases of nonhealing epithelial defects secondary to herpetic keratitis by the administration of fibronectin eyedrops six times a day. The duration of the epithelial defects was 61.5 ± 66.1 days (mean ± SD) before the treatment, and the defects healed within 15.6 ± 12.4 days (Nishida et al., 1985) . Autologous plasma fibronectin eyedrops were thus instituted for the treatment of corneal epithelial disorders at Yamaguchi University Hospital. Our clinical experience with 151 eyes of 146 patients between April 2000 and March 2005 confirmed that fibronectin eyedrops are effective for the treatment of corneal PEDs (72% of 100 eyes responded with complete epithelial resurfacing within 9.5 ± 6.8 days) and simple corneal erosion (91.4% of 35 eyes responded with complete resurfacing within 7.0 ± 6.4 days) (Nishida, 2012) . A representative case is shown in Fig. 4 . The clinical efficacy of such fibronectin treatment has also been reported by others (Kim et al., 1990; McCluskey et al., 1987; Phan et al., 1987) . We have also successfully applied autologous fibronectin eyedrops to the treatment of recurrent corneal erosion (Nishida et al., 1983b) , whereas others (Boisjoly and Beaulieu, 1991) did not find autologous fibronectin to be effective for the treatment of this condition.
More recently, we have administered autologous fibronectin eyedrops to provide a provisional matrix after epithelial debridement in severe cases of ocular allergic disease, recurrent corneal erosion, and lattice corneal dystrophy (Fukuda et al., 2010; Morita et al., 2012) . This is an adjunct use of fibronectin to achieve a rapid and complete epithelial resurfacing after the surgery. Application of fibronectin after refractive surgeries might also facilitate rapid restoration of the corneal epithelium.
Homologous fibronectin eyedrops
Randomized, double-blind clinical trials of homologous fibronectin eyedrops for the treatment of PEDs were performed nationwide in Japan in the early 1990s. Fibronectin eyedrops were prepared from human blood plasma at the New York Blood Center, and virus inactivation was performed to prevent infection. At a concentration of 0.75 mg/mL, fibronectin was found to significantly improve healing. Further drug development was halted, however, because of a requirement from the Japanese health agency for proof of an absolute lack of viral contamination. No trials with homologous fibronectin eyedrops have since been conducted in Japan.
Phase II and III clinical trials of homologous fibronectin eyedrops for corneal PEDs were performed in the United States ( McCulley   Fig. 4 . Autologous fibronectin eyedrops for the treatment of corneal PEDs. Photographs (upper panels) and slitlamp microscopic images of fluorescein staining (lower panels) for a patient with PEDs both before (left panels) and 1 week after (right panels) the initiation of treatment with autologous fibronectin eyedrops. et al., 1993). However, whereas clinical efficacy was demonstrated in the phase II trial, it was not apparent in the phase III study. The protocols for the two studies were a little different, with the fibronectin eyedrops containing a preservative in the phase III trial but not in the phase II trial. Furthermore, homologous fibronectin was compared in the phase III study with frequent application of ointment as the standard treatment. It was thus likely that fibronectin could not overcome the toxicity of the preservative in PED patients. Chiron Ophthalmics also conducted a randomized, double-blind phase II trial of homologous human plasma fibronectin eyedrops containing a preservative for PEDs in the United States. Again, clinical efficacy of the eyedrops was not demonstrated (Gordon et al., 1995) . These studies thus suggest that homologous fibronectin may have efficacy for the treatment of certain types of eye pathology but that the concentration, preservative, and frequency of administration need to be optimized.
Prospects for fibronectin eyedrops
The fibronectineintegrin system plays a central role in corneal epithelial wound healing. The administration of autologous fibronectin eyedrops appears to be clinically effective for the resurfacing of corneal epithelial defects, with the exogenous fibronectin being adsorbed onto the exposed surface of either the stroma or basement membrane and providing a provisional matrix to support both the adhesion and migration of corneal epithelial cells.
It has proven difficult, however, to demonstrate the clinical efficacy of homologous fibronectin eyedrops for the treatment of PEDs. These defects and their underlying causes differ among patients, and it is difficult to enroll patients whose epithelial defects may persist or resurface rapidly before entry into a clinical trial. The concomitant administration of various types of eyedrops with preservatives may also delay epithelial wound closure, with the defects of some patients healing during the washout period (Gordon et al., 1995) .
On the basis of our clinical experience over 3 decades and the results of clinical trials performed in both Japan and the United States, we believe that there is no intrinsic difference between autologous and homologous fibronectin eyedrops. The major concern is that fibronectin is prepared from blood, and that the possibility of contamination with blood-borne viruses or other deleterious factors cannot be ruled out. Given that fibronectin eyedrops are not available commercially, most ophthalmologists are not able to prescribe them. Biochemical knowledge and skill are required to prepare fibronectin eyedrops from a patient's own blood plasma. Although, as far as we are aware, use of autologous fibronectin is safe, the potential problem of contamination exists for homologous fibronectin prepared from pooled blood. We are still using the original technique to prepare autologous fibronectin eyedrops for the treatment of corneal epithelial disorders at Yamaguchi University Hospital. Given that fibronectin is a large glycoprotein, it is currently extremely difficult to synthesize fibronectin by genetic engineering technology, although recombinant human fibronectin might become available for clinical use in the not too distant future.
Autologous serum eyedrops
The application of autologous serum eyedrops has been accepted widely. Growth factors, cytokines, fibronectin, and vitamins that are essential for the maintenance and continuous healing of the corneal epithelium are present in blood serum as well as in tear fluid (Bradley et al., 2008) . Deficiency of such biologically active substances contributes to the pathobiology of various types of corneal epithelial disturbances (Imanishi et al., 2000; Klenkler and Sheardown, 2004; Klenkler et al., 2007) . The administration of blood serum eyedrops to patients with severe corneal epithelial disorders in order to replenish these active substances is thus theoretically well grounded. In 1984, Fox and colleagues reported a beneficial effect of autologous serum eyedrops in patients with dry eye (Fox et al., 1984) . Subsequently, Tsubota and associates as well as others found that such eyedrops were effective for the treatment of severe dry eye and neurotrophic keratopathy (Fox et al., 1984; Geerling et al., 2004; Kojima et al., 2008; Matsumoto et al., 2004; Noda-Tsuruya et al., 2006; Poon et al., 2001; Tsubota et al., 1999a,b; Tsubota and Higuchi, 2000) . Randomized clinical trials provided further evidence for beneficial effects of autologous serum in patients with severe ocular surface disorders (Noble et al., 2004; Tananuvat et al., 2001; Urzua et al., 2012) . However, the clinical improvement described in these various studies was mostly based on subjective assessment. At present, there is no direct evidence to support a beneficial effect of autologous serum eyedrops (Pan et al., 2013 ). As we described in our report of the first successful application of autologous fibronectin eyedrops, we first administered autologous serum eyedrops for 1 week after the diagnosis of trophic ulcer with no beneficial effect (Nishida et al., 1983c) . It is thus possible that serum also contains inhibitory factors that block the stimulatory effect of serum fibronectin on corneal epithelial wound healing. Foulks (2003) commented that "Identification of the specific molecules responsible for the healing effect of serum may allow more specifically targeted therapy in the future." As addressed in the next section, we have identified peptides derived from fibronectin, substance P, and IGF-1 as candidates for the implementation of such targeted therapy.
Activation of epithelial cells to facilitate their migration by peptides
As we have described above, fibronectin facilitates migration of the corneal epithelium both in vitro and in vivo. Although fibronectin eyedrops have been found to be effective for the treatment of nonhealing epithelial defects of the cornea, such eyedrops are not available commercially, largely because fibronectin is purified from blood plasma and it is impossible to eliminate the possibility of contamination with blood-borne viruses. Given that the production of recombinant fibronectin is not yet feasible, an alternative approach to overcoming these problems is to identify an active motif of the fibronectin molecule for use as a synthetic peptide in the clinic.
The fibronectin-derived peptide PHSRN
Identification of PHSRN as a synergy site for the binding of fibronectin to integrin
The complete primary structure of human fibronectin was reported in 1985 (Kornblihtt et al., 1985) , and that of bovine plasma fibronectin in 1986 (Skorstengaard et al., 1986) . Since then, the relation between the molecular structure and biological function of fibronectin has been extensively investigated (Pankov and Yamada, 2002; Schwarzbauer, 1991) .
The ArgeGlyeAsp (RGD) amino acid sequence in 10th type III domain of fibronectin is the main site responsible for binding to the cell surface (Pierschbacher and Ruoslahti, 1984) , a finding that led to the discovery of integrins. In addition to this RGD sequence, however, the ProeHiseSereArgeAsn (PHSRN) sequence in the adjacent 9th type III domain of fibronectin synergistically enhances binding to cells mediated by the RGD sequence and integrin a5b1 (Aota et al., 1994) (Fig. 2) . The requirement for the PHSRN synergy site in a5b1-mediated adhesion to the RGD sequence of fibronectin depends on the activation state of the integrin (Danen et al., 1995) .
The RGD sequence serves to activate and align the integrin a5b1efibronectin interface, and the synergy site provides mechanical strength to the interaction (Garcia et al., 2002) . The PHSRN synergy site is more complex than the small linear RGD peptide sequence (Redick et al., 2000) . A mechanism for integrin a5b1efibronectin interaction, which, in addition to the primary RGD binding event, involves a conformation-sensitive binding of the integrin to accessible sites on the ligand, resulting in full activation of downstream signaling, has been proposed (Altroff et al., 2001) .
A balance between peptide density and steric accessibility of the receptor-binding sequence to integrin a5b1 is required for the strongest adhesion (Dillo et al., 2001) . Indeed, addition of soluble PHSRN peptide together with the RGD peptide did not show a synergistic effect on cell adhesion, whereas the conjugation of these peptides to an amino acid-type poly(ethylene glycol) derivative (aaPEG) revealed that the PHSRN sequence in the PHSRNeaaPEGeRGD molecule synergistically enhanced the cell spreading activity of the RGD sequence (Hojo et al., 2001 ).
Physiological activities of PHSRN
An acetylated and amidated form of the PHSRN peptide (Ac-PHSRN-amide) was found to stimulate the invasion of mouse keratinocytes and fibroblasts into ECM of sea urchin embryos (Livant et al., 2000) . A randomized peptide sequence, Ac-HSPNRamide, as well as forms of the original peptide in which Arg is replaced by either Ala or Glu were inactive in this assay. Topical application of Ac-PHSRN-amide also accelerated dermal wound healing in genetically obese, diabetic (C57BL6/KsJ db/db) mice, in which wound healing is delayed compared with that in control (C57BL6) mice. The peptide Ac-PHSCN-amide was found to inhibit both PHSRN-and serum-induced invasion of prostate carcinoma cells in vitro in a competitive manner, and intravenous injection of Ac-PHSCN-amide significantly inhibited tumor growth and neovascularization in vivo, suggesting that this peptide may be a potent antitumorigenic and antimetastatic agent (Livant et al., 2000) .
Synergy between the RGD and PHSRN sequences of fibronectin is important for macrophage adhesion, with these two peptides having been found to recapitulate the activity of the full-length fibronectin molecule. Macrophage adhesion to an oligomer containing both RGD and PHSRN sequences (GGGRGDG GGGGGPHSRNG) was found to be mediated by activation of both protein kinase C (PKC) and extracellular signal-regulated kinase (ERK) signaling pathways Kao and Liu, 2001 ). The interaction of fibronectin with integrin a5b1 in monocytes stimulates the production of angiogenic CXC chemokines (including IL-8, epithelial neutrophil-activating peptide-78, growth-related oncogene a, and growth-related oncogene g) but not that of vascular endothelial growth factor (White et al., 2001) .
Effects of PHSRN on corneal epithelial cells
We have investigated the effects of the synthetic peptide Ac-PHSRN-amide on corneal epithelial migration both in vitro and in vivo. We found that exogenous Ac-PHSRN-amide stimulated corneal epithelial migration in our organ culture system for the rabbit cornea in a concentration-dependent manner. The stimulatory effect of Ac-PHSRN-amide at 0.2 or 2 mM was identical to that of either human plasma fibronectin at 0.1 mM or recombinant human EGF at 0.1 mM. The reverse-sequence peptide, Ac-NRSHPamide, was inactive in this assay. The addition of Ac-PHSRNamide (2 mM) to HCE cells in culture also increased cell motility in association with the formation of membrane ruffles at the cell periphery (Kimura et al., 2007) .
We examined the sequence specificity of the effect of PHSRN on corneal epithelial migration. Elongation and deletion analyses of Ac-PHSRN-amide indicated that the five-amino acid sequence (PHSRN) was the minimum essential sequence for promotion of corneal epithelial migration. Alanine substitution analysis revealed that the Ser and Arg residues are critical for the biological activity of PHSRN. Furthermore, the N-acetyl and C-amide groups of Ac-PHSRN-amide are important for the chemical stability of the peptide in tear fluid ). These findings thus suggested that Ac-PHSRN-amide had therapeutic potential for the promotion of corneal wound healing.
We also examined the effect of the PHSRN peptide on HCE cell adhesion to a fibronectin matrix. Neither PHSRN nor NRSHP at concentrations of 1e1000 mM had a significant effect on cell adhesion to fibronectin. In contrast, the GRGDSP peptide, but not the control GRGESP peptide, inhibited adhesion of HCE cells to fibronectin in a concentration-dependent manner (Kimura et al., 2007) .
Immortalized rabbit corneal epithelial cells adhere to a chemically synthesized collagen-like polypeptide, poly(-prolylehydroxyprolyleglycyl), or poly(ProeHypeGly). Conjugation of GRGDS to poly(ProeHypeGly) increased the adhesion of corneal epithelial cells to the polypeptide, and conjugation of both GRGDS and PHSRN increased adhesion even further. The addition of soluble GRGDS inhibited adhesion of the epithelial cells to fibronectin, whereas that of soluble PHSRN had a smaller inhibitory effect. These results thus confirmed the key role of the RGD sequence and the secondary role of the PHSRN sequence in the adhesion of corneal epithelial cells to fibronectin (Shibasaki et al., 2011) .
We found that the PHSRN peptide induced the formation of a thick rim of actin filaments in a dense meshwork at the leading edge of HCE cells. Co-staining with antibodies to phosphotyrosine revealed numerous small dotlike structures, presumably corresponding to focal adhesions, associated with the bundles of F-actin at the cell periphery. Immunoblot analysis showed that the PHSRN peptide increased the tyrosine phosphorylation of both focal adhesion kinase (FAK) and paxillin in HCE cells compared with that apparent in the presence of the NRSHP peptide (Kimura et al., 2007) . PHSRN also increased the levels of HSP70 (heat shock protein of 70 kDa) mRNA and protein in these cells in a concentrationand time-dependent manner, whereas NRSHP did not. The PHSRNinduced up-regulation of HSP70 was blocked by SB203580, an inhibitor of p38 mitogen-activated protein kinase (MAPK), but it was not affected by PD98059 or SP600125, inhibitors of signaling by the MAPKs ERK and c-Jun NH 2 -terminal kinase (JNK), respectively (Ko et al., 2008c) . These results suggested that the induction of HSP70 expression might contribute to the promotion of corneal epithelial migration by PHSRN and hence to corneal epithelial wound healing. Furthermore, PHSRN increased the expression of the tight-junction protein ZO-1 (zonula occludens-1) at both mRNA and protein levels and in a concentration-and time-dependent manner in HCE cells, whereas it had no effect on that of the tight-junction proteins ZO-2, ZO-3, claudin, or occludin. Immunofluorescence microscopy showed that the PHSRN peptide did not affect the localization of ZO-1 at the interfaces of neighboring cells. The up-regulation of ZO-1 expression by PHSRN was blocked by inhibitors of ERK (PD98059), p38 (SB203580), and JNK (JNK inhibitor II) signaling, consistent with the finding that the peptide induced the phosphorylation of these MAPKs as well as that of c-Jun. The PHSRN peptide had no effect on the transepithelial electrical resistance of cultured HCE cells. The PHSRN peptide thus induced expression of ZO-1 in a manner dependent on MAPK signaling, and this effect may contribute to the formation of tight junctions between corneal epithelial cells during their differentiation and after their migration during wound healing (Yanai et al., 2009 ).
PHSRN eyedrops for the treatment of PEDs
Administration of the Ac-PHSRN-amide peptide in eyedrops promoted corneal epithelial wound closure in rabbits in a dosedependent manner, whereas the control peptide Ac-NRSHPamide had no such effect (Kimura et al., 2007) . These observations suggested that the PHSRN peptide mimics the effect of fibronectin on this process and may prove suitable as a substitute for fibronectin in the treatment of PEDs of the cornea.
On the basis of our in vitro and in vivo results with the PHSRN peptide, we undertook a clinical study at Yamaguchi University Hospital. Eyedrops containing Ac-PHSRN-amide (0.02%) in phosphate-buffered saline were administered four times a day to seven patients with PEDs. The duration of the PEDs before treatment was 7.4 ± 5.5 (mean ± SD) weeks. Five out of the seven treated eyes (71%) responded well to the regimen, with complete epithelial resurfacing being achieved within 4 weeks after treatment initiation. Indeed, the time required for complete epithelial resurfacing in the five responding subjects was 15.8 ± 3.4 days. No adverse effects of the treatment were observed in any of the subjects. A representative case is shown in Fig. 5 . This open clinical study demonstrated that eyedrops containing the fibronectinderived peptide Ac-PHSRN-amide are clinically effective for the treatment of PEDs . This finding will require confirmation by a well-controlled, double-masked, multicenter clinical trial before the treatment can be established for patients with PEDs.
The mechanisms of action of fibronectin and the PHSRN peptide in the promotion of corneal epithelial wound healing appear to be completely different. Administration of fibronectin provides a provisional matrix for epithelial migration, with the RGD motif of the exogenous fibronectin binding to integrin and activating intracellular signaling that leads to the active movement of the epithelial cells. On the other hand, administration of the PHSRN peptide results in modulation of the binding of cell surface integrin to the RGD motif of endogenous fibronectin. Whether or not the concomitant administration of fibronectin as a matrix together with the PHSRN peptide as a modulator might be more effective than treatment with either agent alone warrants further investigation in the clinical setting.
5.2. Substance P and IGF-1 5.2.1. Clinical basis for study of substance P During our treatment of patients with PEDs of the cornea by the administration of autologous fibronectin eyedrops, we recognized that most of these patients manifested a reduced corneal sensation. This clinical experience led us to investigate the role of corneal innervation by the trigeminal nerve in corneal epithelial wound repair.
The cornea is innervated by the ophthalmic branch of the trigeminal nerve. It is also the most sensitive tissue of the body (Marfurt et al., 2010; Muller et al., 2003) , with the density of nerve endings at the surface of the human cornea being~6500/mm 2 , which is 300e400 times as high as that in the skin (de Castro et al., 1998; Muller et al., 1997; Rozsa and Beuerman, 1982) . Immunohistological studies have revealed the presence of various neurotransmitters in the cornea including substance P, calcitonin generelated peptide (CGRP), and acetylcholine (Beckers et al., 1993; Ehinger et al., 1983; Keen et al., 1982; Kuwayama and Stone, 1987; Lehtosalo, 1984; Miller et al., 1981; Sakiyama et al., 1984; Sasaoka et al., 1984; Shimizu, 1982; Shimizu et al., 1982; Stone and Kuwayama, 1985; Stone et al., 1982; Stone and McGlinn, 1988; Tervo et al., 1981 Tervo et al., , 1982a Tervo et al., ,b, 1983 Tornqvist et al., 1982; Ueda et al., 1989) . We became interested in the role of substance P in the physiology of corneal epithelial cells, because substance P is also a neurotrophic factor. It was first identified in 1931 in both the brain and small intestine of horses as a factor that lowers blood pressure and stimulates contraction of the intestine (V. Euler and Gaddum, 1931) . It is a member of the tachkinin family of peptides and comprises 11 amino acids (Chang et al., 1971; Kahl and Reid, 1995; Nakanishi, 1991) .
Various early studies recognized that pathology at any level of the trigeminal nerve, including the nucleus, ganglion, and nerve fibers, is associated with loss of corneal sensation and corneal epithelial lesions (Jaffe, 1938; Magendie, 1824; Pannabecker, 1944; Paton, 1926; Turner, 1895) . Denervation of the trigeminal nerve was also found to result in reduced mitotic activity of corneal epithelial cells in the rabbit (Mishima, 1957) , and denervation of the rabbit cornea increased epithelial permeability and retarded epithelial wound closure (Beuerman and Schimmelpfennig, 1980) . Various types of corneal epithelial disorders including PEDs have been found to result from insults to the trigeminal nerve and are known collectively as neurotrophic keratopathies (Belmonte et al., 2004a) . Clinical causes of loss or impairment of trigeminal nerve function and reduced corneal sensation include herpes simplex virus or herpes zoster ophthalmicus virus infection (Cobo, 1988; Holland and Schwartz, 1999; Liesegang, 1985) ; complications of surgery for acoustic neurioma or trigeminal neuralgia (Blau et al., 1969; Rosenberg et al., 1981) or of ophthalmic surgeries such as penetrating keratoplasty, LASIK, and photorefractive keratectomy Fig. 5 . PHSRN eyedrops for the treatment of corneal PEDs. Photographs (upper panels) and slitlamp microscopic images of fluorescein staining (lower panels) for a patient with PEDs both before (left panels) as well as 3 (center panels) and 17 (right panels) days after the initiation of treatment with Ac-PHSRN-amide eyedrops. (Benitez-del-Castillo et al., 2001; Bragheeth and Dua, 2005; Campos et al., 1992; Chao et al., 2014; Chuck et al., 2000; Ishikawa et al., 1994; Kalyvianaki et al., 2006; Kohlhaas, 1998; Kumano et al., 2003; Lee et al., 2006; Linna et al., 2000; Mathers et al., 1988; Matsui et al., 2001; Melki and Azar, 2001; Nassaralla et al., 2003; Nejima et al., 2005; Rao et al., 1985; Stachs et al., 2010; Tugal Tutkun et al., 1993; Vestergaard et al., 2013; Wilson, 2001) ; thermal or chemical burns of the cornea; toxic keratopathy such as that resulting from abuse of topical anesthetics or bblockers (Chen et al., 2004; Rosenwasser, 1989; Spinelli et al., 1984; Van Buskirk, 1979; Willis and Laibson, 1970) ; contact lens wear; diabetes mellitus (Cousen et al., 2007; Davidson et al., 2012a,b; McNamara et al., 1998; Nielsen, 1978; Saito et al., 2003) ; aging (Kotulak and Brungardt, 1980; Roszkowska et al., 2004) ; some types of corneal dystrophy such as lattice dystrophy; and congenital diseases such as Riley-Day syndrome (Ramaesh et al., 2007) . The structure and physiology of corneal innervations (Belmonte et al., 2004a,b; Mensher, 1974; Muller et al., 2003; Shaheen et al., 2014) as well as neurotrophic keratopathy (Chang and Groos, 2011; Daniele et al., 1992; Goins, 2005; Lambiase et al., 1999; Lockwood et al., 2006; Nishida and Yanai, 2009; Okada et al., 2010; Pushker et al., 2001; Sacchetti and Lambiase, 2014) have been extensively reviewed elsewhere.
The possible roles of impaired corneal sensitivity and reduced tear secretion in corneal epithelial disorders (PEDs, erosion, or SPK) have been investigated in the clinical setting. Corneal sensitivity was found to be significantly reduced in patients with PEDs or corneal erosion compared with control individuals. On the other hand, the Schirmer test revealed that tear secretion was significantly reduced in SPK patients compared with controls . These findings suggested that a loss of corneal sensitivity might contribute to the development of PEDs and corneal erosion, whereas reduced tear secretion may be a contributing factor for SPK. They further indicate the importance of signals derived from corneal nerve endings for maintenance of the normal structure and function of the cornea and for corneal wound repair.
Role of substance P in corneal epithelial migration
The physiological relevance of corneal innervation to the maintenance and healing of the corneal epithelium was investigated by examination of the effects of the sensory neurotransmitter substance P on epithelial migration in organ culture, on the attachment of corneal epithelial cells to various ECM proteins, and on corneal epithelial cell proliferation.
We found that substance P at all concentrations examined (10e50 mg/mL) had no effect on migration of the rabbit corneal epithelium in organ culture. Given that the cornea is regulated by various biologically active substances in tear fluid as well as by neural factors released from corneal nerve fibers, we also investigated the effects of various growth factorsdincluding IGF-1, IGF-2, insulin, EGF, basic FGF, and transforming growth factor-b (TGF-b)d on corneal epithelial migration in the absence or presence of substance P. In the absence of substance P, only EGF among the tested growth factors stimulated epithelial migration. In the presence of substance P, however, epithelial migration was enhanced by EGF, IGF-1, and IGF-2 compared with that apparent in the presence of each growth factor alone. Insulin, basic FGF, and transforming growth factor-b did not affect epithelial migration in the absence or presence of substance P. This synergistic effect of EGF or IGF-1 together with substance P was found to be dependent on the concentration of each agent (Nakamura et al., 1997a; Yamada et al., 2004) . The synergism of substance P with IGF-1 was specific in that no other neurotransmitter examineddincluding vasoactive intestinal Table 2 Activity of neurotransmitters, tachykinins, and peptides derived from substance P in synergistic promotion together with IGF-1 of rabbit corneal epithelial migration in organ culture. peptide, CGRP, acetylcholine, norepinephrine, and serotonindpromoted corneal epithelial migration in the presence of IGF-1. Furthermore, other tachkinin family membersdincluding neurokinin A, neurokinin B, kassinin, eledoisin, and physalaemindhad no effect on corneal epithelial migration in the absence or presence of IGF-1 (Table 2) . Corneal epithelial cells attach to a greater extent to fibronectin, collagen type I, and laminin matrices than to bovine serum albumin as a control. Culture of HCE cells in the presence of either substance P or IGF-1 alone had no significant effect on the number of cells attached to these ECM proteins. The addition of both substance P and IGF-1, however, resulted in a marked increase in the number of attached cells . Attachment of HCE cells to a fibronectin matrix is inhibited by addition of the GRGDSP peptide, which is derived from the cell-binding domain of fibronectin that interacts with integrin a5b1 (Kimura et al., 2007; Nishida et al., 1988) . We found that the combination of substance P and IGF-1 increased the amount of integrin a5 mRNA, without affecting that of integrin b1 mRNA, in HCE cells. Substance P or IGF-1 alone had no effect on the abundance of either integrin mRNA (Nakamura et al., 1998a) . Furthermore, the combination of substance P and IGF-1 up-regulated phosphorylation of focal adhesion kinase (FAK) and paxillin in HCE cells (Nakamura et al., 1998b) . Together, these findings thus demonstrated that the combination of substance P and IGF-1 up-regulates and activates integrin a5 in corneal epithelial cells, and that it increases both the adhesion of these cells and promotes corneal epithelial migration. The combination of substance P and IGF-1 had no effect on the mitotic activity of corneal epithelial cells as determined by measurement of [ 3 H]thymidine uptake .
Amino acid sequence
Among neurokinin receptors, NK-1 is the primary receptor for substance P in rabbit corneal epithelial cells. The addition of an NK-1 antagonist inhibited the synergistic effect of substance P and IGF-1 on rabbit corneal epithelial migration in organ culture, whereas an NK-2 antagonist was inactive, implicating NK-1 in mediation of this action of substance P (Nakamura et al., 1997c) . Analysis of signaling downstream of NK-1 revealed that the action of substance P was prevented by inhibitors of phospholipase C, of the inositol 1,4,5-triphosphate receptor-mediated release of Ca 2þ from intracellular stores, and of Ca 2þ -and calmodulindependent protein kinase II (Yamada et al., 2005) . The effect of substance P in the synergistic action with IGF-1 on corneal epithelial migration was thus found to be mediated by a signaling pathway triggered by NK-1 that leads to the activation of this protein kinase. Further studies revealed that the PKC inhibitors calphostin C and H-7 as well as the tyrosine kinase inhibitors genistein and herbimycin A attenuated the synergistic effect of substance P and IGF-1 on corneal epithelial migration, implicating both PKC and tyrosine kinase signaling pathways in this effect (Ofuji et al., 2000) . Finally, inhibition of p38 MAPK signaling, but not that of ERK signaling, attenuated the stimulation of corneal epithelial migration by substance P and IGF-1 (Nakamura et al., 2005) . To translate these in vitro studies to the clinic, we examined the effect of the administration of eyedrops containing substance P and IGF-1 on rabbit corneal epithelial resurfacing in vivo. We removed the corneal epithelium with n-heptanol and then applied eyedrops containing either substance P (1 mg/mL), IGF-1 (1 mg/ mL), the combination of substance P and IGF-1, or phosphate buffered saline as a control. The healing rate of epithelial defects was significantly greater in eyes treated with substance P and IGF-1 compared with those treated with substance P alone, with IGF-1 alone, or with phosphate-buffered saline, demonstrating that the combination of substance P and IGF-1 stimulated the resurfacing of corneal epithelial defects in healthy rabbits (Nakamura et al., 1997b) (Table 3) . We further investigated the effects of eyedrops containing substance P and IGF-1 in a rat model of neurotrophic keratopathy induced by capsaicin. Topical application of the combination of substance P (1 mM) and IGF-1 (1 mg/mL) in phosphate-buffered saline improved both corneal epithelial barrier function and epithelial wound healing in this animal model (Nakamura et al., 2003b) . We established another rat model of neurotrophic keratopathydcharacterized by reduced tear secretion, loss of corneal sensation, impaired epithelial barrier function, and delayed epithelial wound healingdby thermocoagulation of the ophthalmic branch of the trigeminal nerve. Application of eyedrops containing substance P and IGF-1 to the denervated cornea restored fluorescein permeability of the corneal epithelium to control levels (that is, improved barrier function) and abolished the delay in epithelial wound healing (Nagano et al., 2003) . Together, these results thus showed that topical administration of both substance P and IGF-1 promotes epithelial wound closure in vivo regardless of whether the trigeminal nerve is intact or not.
5.2.3. Identification of minimum essential amino acid sequences of substance P and IGF-1 required for synergistic promotion of corneal epithelial migration Substance P is a constituent of sensory nerve fibers and has been postulated to mediate various physiological functions including vasodilation and inflammation (Payan, 1989; Pernow, 1983) . However, it is readily degraded and inactivated by neuropeptidases such as carboxypeptidases and endopeptidases (Guyon et al., 1979; Matsas et al., 1983 Matsas et al., , 1984 . The identification of smaller and more stable peptides that retain biological activity would thus be expected to facilitate the clinical development of substance P.
IGF was originally known by various names based on its activities, such as sulfation factor (and later, somatomedin C) (Daughaday et al., 1972; Salmon and Daughaday, 1957) , nonsuppressible insulin-like activity (Froesch et al., 1963) , and multiplication-stimulating activity (Pierson and Temin, 1972) . The term insulin-like growth factor was proposed in 1976 (Rinderknecht and Humbel, 1976) . As this historical overview shows, IGF isoforms have a wide variety of physiological functions in the body (Daughaday and Rotwein, 1989; LeRoith et al., 1991) . They thus contribute to regulation of the proliferation, differentiation, survival or apoptosis (Kooijman, 2006) , migration (Jones et al., 1995) , or adhesion (Mauro et al., 2003) of most cell types, as well as play important roles in metabolism (Clemmons, 2012) , morphogenesis, development, wound healing, and osteogenesis (Al-Kharobi et al., 2014) . Clinical application of IGF-1 might therefore be expected to be associated with undesirable side effects. Identification of the minimum essential amino acid sequence of IGF-1 for a particular desired effect might minimize the likelihood of the development of such adverse effects.
We therefore adopted a similar strategy to delineate partial amino acid sequences of substance P and IGF-1 responsible for the synergistic stimulation of corneal epithelial migration.
5.2.3.1. FGLM-amide: a peptide derived from substance P. Substance P comprises the 11-amino acid sequence ArgeProeLyseProeGlneGlnePheePheeGlyeLeueMeteamide.
The ability of short peptides derived from the carboxyl terminus of substance P to reproduce the vasodilator, spasmogenic, and venoconstrictor activities of the full-length molecule were investigated. The carboxyl-terminal tripeptide (GLM-amide) and tetrapeptide (FGLM-amide) were found to possess weak vasodilator activity, the pentapeptide (FFGLM-amide) to exert substantial spasmogenic and vasoactive effects, and peptides with six or more amino acids to possess activities identical to the intact molecule (Bury and Mashford, 1976) . We similarly set out to identify the minimum amino acid sequence of substance P necessary for the synergistic effect with IGF-1 on corneal epithelial migration (Nakamura et al., 1997a) .
We found that a peptide containing the seven amino acids at the amino terminus of substance P did not affect epithelial migration in the absence or presence of IGF-1 in the rabbit corneal organ culture system (Table 2 ). In contrast, peptides comprising residues 5e11, 6e11, 7e11, and 8e11 showed synergy with IGF-1 in the promotion of corneal epithelial migration, whereas the tripeptide derived from the carboxyl terminus did not. These results thus identified the four-amino acid sequence FGLM-amide at the carboxyl terminus of substance P as the minimum essential sequence for synergism with IGF-1.
Tachykinins share the characteristic amino acid sequence PheeXeGlyeLeueMeteamide at the carboxyl terminus, with this portion of the molecular structure of tachykinins being essential for many of their biological activities (Severini et al., 2002) . Neurokinin A and B as well as kassinin thus contain the sequence VGLM-amide at the carboxyl terminus, whereas eledoisin contains IGLM-amide and physalaemin contains YGLM-amide. In contrast to the FGLMamide peptide derived from substance P, peptides corresponding to these various four-amino acid sequences did not show a synergistic effect with IGF-1 on corneal epithelial migration (Table 2 ) .
We also found that, like the combination of substance P and IGF-1, the combination of FGLM-amide and IGF-1 significantly increased the attachment of HCE cells to a fibronectin matrix and up-regulated the abundance of integrin a5 mRNA in these cells . Furthermore, the administration of eyedrops containing FGLM-amide and IGF-1 accelerated corneal epithelial wound closure in rabbits as well as did those containing substance P and IGF-1 . In rats with streptozotocininduced diabetes, in which epithelial wound closure is delayed, the administration of eyedrops containing FGLM-amide plus IGF-1 facilitated corneal epithelial wound healing, suggesting that such treatment might prove effective in humans with diabetic keratopathy (Nakamura et al., 2003a) (Table 3) .
Substance P induces miosis, or a decrease in pupil size (Soloway et al., 1981) . We found that instillation of substance P significantly reduced pupil size in rabbits whether or not IGF-1 was present. However, FGLM-amide with or without IGF-1 did not affect pupil size , indicating that this partial amino acid sequence of substance P retains the desired biological activity of synergistic promotion with IGF-1 of corneal epithelial migration, but that it lacks the undesired miotic effect. On the basis of these results, we concluded that a peptide corresponding to the fouramino acid sequence at the carboxyl terminus of substance P (FGLM-amide) was a feasible substitute for the full-length molecule for clinical use.
5.2.3.2. SSSR: a peptide derived from IGF-1. Members of the insulin family of proteins, including insulin, IGF-1, and IGF-2, have highly similar amino acid sequences (~50% identity) and molecular Table 4 Comparison of the amino acid sequences of human proinsulin, IGF-1, and IGF-2.Common sequences are shown in bold and underlined.
B domain
GIVEECCFRSCDLALLEYYCAT-PAKSE structures. Human IGF-1 consists of a single chain of 70 amino acids with a molecular size of 7649 Da (Rinderknecht and Humbel, 1978) (Fig. 6) . A key difference between the molecular structure of insulin and those of IGF-1 and IGF-2 is the presence of a D domain in the latter proteins. In addition, although proinsulin, like IGF-1 and IGF-2, possesses a C domain, this region is removed during the processing of proinsulin to insulin, resulting in the double-chain structure of insulin (Table 4) . We found that both IGF-1 and IGF-2 exhibit a synergistic effect together with substance P or the substance P-derived peptide FGLM-amide on corneal epithelial migration in the organ culture system for the rabbit cornea, whereas insulin was inactive in this regard. Furthermore, a 12-amino acid peptide corresponding to the C domain of IGF-1 (Gly 30 eThr 41 ) mimicked this effect of full-length IGF-1 in the presence of FGLM-amide, whereas the C peptide of proinsulin or the D domain of IGF-1 did not. Eyedrops containing FGLM-amide and either intact IGF-1 or a peptide corresponding to the C domain of IGF-1 were also found to promote epithelial wound closure in rabbits, whereas the C domain alone was inactive (Yamada et al., 2004 , or Arg 36 with Ala resulted in loss of the synergistic effect with FGLM-amide, whereas replacement of Gly 32 or Arg 37 had no effect on synergism. We therefore concluded that the four-amino acid sequence SSSR is necessary and sufficient for the synergistic action of IGF-1 with substance P on corneal epithelial migration. Changes to the order of these four amino acids also resulted in a loss of synergy, indicating the importance of the precise SSSR sequence. The combination of FGLM-amide and SSSR peptides was found to be effective for the promotion of epithelial wound closure in vivo. Furthermore, whereas IGF-1 induces the formation of prominent new vessels when injected into the corneal stroma, topical application of the SSSR peptide did not result in such an effect. Shortening of the fulllength IGF-1 molecule to just the tetrapeptide SSSR thus retains the synergistic effect with substance P on corneal epithelial wound healing but results in a loss of angiogenic activity (Yamada et al., 2006) . Our data further revealed that substance P or the substance Pderived peptide FGLM-amide sensitizes epithelial cells to the induction of migration by IGF-1 or the C-domain peptide, shifting the concentrationeresponse curve for IGF-1 or the C-domain peptide to the left (Yamada et al., 2005) (Fig. 7) . A stimulatory effect of IGF-1 alone on corneal epithelial migration was thus apparent at unphysiologically high concentrations (!1 mM) of the growth factor, which are about four orders of magnitude greater than those found to be effective in the presence of substance P. This sensitizing effect of substance P was also apparent with the induction of corneal epithelial migration by other biological agents including fibronectin and IL-6 (Yamada et al., 2005) .
The action of the C-domain peptide of IGF-1 or the SSSR tetrapeptide in the synergistic promotion of corneal epithelial migration was found not to be mediated by the IGF-1 receptor, given that these peptides failed to induce phosphorylation of Akt, a downstream effect of IGF-1 receptor activation in HCE cells (Yamada et al., 2004) . Moreover, a mutant form of IGF-1 in which Ser 34 is replaced by Ala does not manifest a synergistic effect with substance P on corneal epithelial migration even though it retains the ability to activate the IGF-1 receptor. Clinical application of the SSSR peptide would thus be expected to be free of potentially deleterious side effects associated with treatment with full-length IGF-1.
Clinical application of substance P plus IGF-1 or of derived peptides for treatment of corneal PEDs
The first patient treated with eyedrops containing substance P and IGF-1 was a 16-month-old girl with severe neurotrophic and anhidrotic keratopathy who had central epithelial defects (5 by 5 mm) in both eyes. Despite intensive lubrication and application of bandage contact lenses, rapid stromal melting occurred bilaterally, leading to the development of a central descemetocele in the right eye. In an attempt to save the remaining left eye, eyedrops containing substance P (250 mg/mL) in balanced salt solution were administered, but no improvement was apparent after 10 days.
Insulin (3 mg/mL) was then added to the substance P eyedrops, again without any improvement. The treatment was then changed to eyedrops containing substance P (250 mg/mL) and IGF-1 (25 ng/ mL). The lesion in the left eye began to undergo visible epithelialization within 5 days, and complete epithelialization was achieved after 30 days. Three months later, the corneal epithelium remained intact and the central stroma was less opaque (Brown et al., 1997) . These clinical findings were thus identical to those previously obtained in vitro; that is, only the combination of substance P and IGF-1 promoted corneal epithelial migration, with substance P either by itself or in combination with insulin being inactive.
Given that our preclinical studies showed that the substance Pderived peptide FGLM-amide mimics the parent molecule, we also administered eyedrops containing FGLM-amide and IGF-1 to a 55-year-old woman with large corneal PEDs in her left eye associated with neurotrophic keratopathy due to trigeminal nerve palsy. Her visual acuity was 2/100 with stromal edema. Two days after the initiation of treatment with eyedrops containing both FGLMamide (1 mg/mL) and IGF-1 (1 mg/mL) four times a day, visible epithelial resurfacing had begun. After 1 week, the epithelial defects were <10% of their original size, and complete epithelial resurfacing was achieved within 2 weeks. The stromal edema started to subside thereafter, with corneal transparency being achieved after 4 weeks. The patient's visual acuity returned to 20/ 50 (Chikama et al., 1998) .
The clinical efficacy of eyedrops containing FGLM-amide and IGF-1 for the treatment of PEDs in individuals with neurotrophic keratopathy was examined in a prospective open study. Eleven patients (11 eyes) with PEDs associated with neurotrophic keratopathy were treated for up to 28 days by the administration of eyedrops containing FGLM-amide (1 mg/mL) and IGF-1 (1 mg/mL).
Complete epithelial resurfacing was achieved in eight of the nine (89%) cases that showed a response. The defects were completely resurfaced in two of the nine (22%) and five of the nine (56%) cases within 1 and 2 weeks, respectively, after treatment initiation. No adverse effects were observed in any of the 11 patients. This trial thus showed that eyedrops containing FGLM-amide and IGF-1 induced the rapid resurfacing of PEDs in individuals with neurotrophic keratopathy .
Our finding that the tetrapeptide SSSR derived from the C domain of IGF-1 mimics the intact molecule prompted us to undertake a prospective open study of the clinical efficacy of eyedrops containing FGLM-amide (1 mg/mL) and SSSR-trifluoroacetate (0.05629 mg/mL) in phosphate-buffered saline for the treatment of PEDs in individuals with neurotrophic keratopathy. Twenty-five consecutive patients (26 eyes) were enrolled in the study. The epithelial defects resurfaced completely in 19 of the 26 eyes (73%) within 4 weeks after treatment initiation. Complete resurfacing of the defects was apparent in 18 of 22 (82%) or in one of four (25%) eyes without or with limbal stem cell deficiency, respectively. No adverse effects of treatment were observed in any of the subjects. Eyedrops containing FGLM-amide and SSSR were thus shown to induce the rapid resurfacing of PEDs in stem cell-positive individuals with neurotrophic keratopathy (Yamada et al., 2008) . A representative case is shown in Fig. 8 .
The efficacy of eyedrops containing peptides based on substance P (FGLM-amide) and IGF-1 (SSSR) for prevention of SPK after cataract surgery in individuals with type 2 diabetes was also examined. Twenty-nine patients (29 eyes) with diabetes were enrolled in a double-masked, prospective, randomized, placebocontrolled clinical study. They were randomly assigned to one of two groups that received eyedrops containing either FGLM-amide and SSSR (n ¼ 14) or phosphate-buffered saline (n ¼ 15) four times a day for 14 days beginning 1 day after phacoemulsification. SPK scores (area, density, and combined area and density) were determined (Miyata et al., 2003) . SPK scores did not differ between the two groups before surgery or before initiation of treatment. At day 2 after treatment initiation, all SPK scores were significantly lower in the FGLM-amide-SSSR group than in the control group. The density score was also significantly lower in the former group at day 7 after surgery. All scores returned to preoperative levels by day 14 after surgery in both groups. Our study thus showed that eyedrops containing FGLM-amide and SSSR are effective for the prevention of SPK after cataract surgery in diabetic patients (Chikamoto et al., 2009 ).
Development of new peptide drugs for the treatment of PEDs of the cornea
Among the various types of corneal epithelial disorders, PEDs remain the most difficult to treat, with the persistence of these defects being a manifestation of underlying disease. Furthermore, loss of the corneal epithelium may result in the activation of keratocytes in the corneal stroma and lead to the development of ulceration and perforation. It is thus essential to restore the continuity of the epithelium and to protect corneal structure and function from further degradation in order to save the vision of affected individuals. Currently available therapeutic approaches are largely based on protection of the ocular surface by lubrication, contact lens wear, tarsorrhaphy, or viscous solution application. Progress in cell and molecular biology over the last several decades now allows us to discuss the underlying mechanisms of PEDs in terms of the cells and molecules involved, with fibronectineintegrin interactions having been found to play a central role in corneal epithelial wound healing. Corneal PEDs are characterized by a loss of epithelial cell adhesion to the underlying matrix, by excessive degradation of matrix proteins associated with inflammation, and by the inability of epithelial cells to initiate migration. On the basis of these characteristics, two types of new therapeutic approach can be considered: the provision of an appropriate substrate to serve as a provisional matrix for the attachment and migration of epithelial cells, and the activation of epithelial cells to up-regulate integrin receptors for ECM proteins (Fig. 9) .
In this review, we have discussed fibronectin as a candidate exogenous substrate to promote the attachment and migration of corneal epithelial cells. Whereas corneal epithelial cells are able to attach to basement membrane proteins including fibronectin, laminin, and collagen types I and IV, fibronectin is the most effective of these proteins for stimulating cell motility. To overcome the practical problems associated with the production of fibronectin eyedrops, we have developed a peptide corresponding to the second cell-binding site of fibronectin and shown it to be effective in facilitating the migration of corneal epithelial cells. The early clinical results obtained with such PHSRN eyedrops for the treatment of PEDs are encouraging, but double-masked, multicenter clinical trials are required to establish them for use in the clinic.
We have also shown that eyedrops containing the combination of substance P and IGF-1 are effective for the treatment of corneal PEDs. Furthermore, by identifying the minimum amino acid sequence required for this activity of both substance P and IGF-1, we have developed eyedrops containing the combination of two peptides, FGLM-amide from substance P and SSSR from IGF-1. The clinical use of peptides instead of the intact parent molecules has several advantages, including the potential elimination of unwanted side effects. Furthermore, small peptides are more stable than full-length proteins and are less expensive to produce.
Two organizations, academia and industry, play key complementary roles in drug development, as exemplified by our strategy for the development of peptide drugs for the treatment of nonhealing corneal epithelial defects (Fig. 10) . Most clinical trials conducted at academic institutions are open studies of treatment modalities, whereas pharmaceutical companies are better equipped to perform the large-scale, well-controlled, double-masked trials required for drug approval because of the large financial and manpower resources that are needed for these studies.
Ophthalmologists often experience cases for which the currently available prescription drugs or surgical maneuvers do not effectively cure the patient. Whether the number of such patients is small or large, they reveal an unmet need for new treatments. Intensive observation of these patients may shed light on the underlying pathological mechanism that gives rise to the untreatable condition as well as suggest targets for new drug development. Such proposed mechanisms and targets can then be evaluated by scientists in the laboratory, with such evaluation including screening for potential therapeutic agents with the use of in vitro systems such as cell or organ culture. Identification of such candidate agents in in vitro systems can then be followed by examination of their effectiveness in animal models. Remaining agents are then returned to ophthalmologists for the performance (with Institutional Review Board approval) of clinical studies (mostly, open studies) to determine whether they are indeed effective for treatment of the disease or condition in the clinical setting.
Ophthalmologists and scientists in academia may attempt to modify the original drug to obtain one with a simpler chemical structure, greater specific activity, or fewer adverse effects, at which point further drug development is usually undertaken by industry. Industry thus performs additional preclinical studies, a phase I trial for evaluation of drug safety in normal human volunteers, phase IIa and phase IIb trials for determination of the correct dose and evaluation of clinical efficacy as well as safety, and, finally, a multicenter, double-masked phase III trial. If the results of the various trials are satisfactory, the drug is submitted for approval by the relevant governmental health authority. The major concern of industry is clinical efficacy of the drug in a large number of patients as well as its marketability and profitability, and the company may abandon development of a new drug at any stage depending on the anticipated amount of time and money required to bring it to market. Disclosures T.N. holds patents on FGLM-amide and SSSR, and PHSRN. M.I. holds patent on FGLM-amide and SSSR. M.N. has no conflict of interest.
